模拟胰淀素和胰高血糖素样肽1作用的新兴疗法。 - Suppr

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.

作者信息

Riddle Matthew C, Drucker Daniel J

机构信息

Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon, USA.

出版信息

Diabetes Care. 2006 Feb;29(2):435-49. doi: 10.2337/diacare.29.02.06.dc05-1267.

DOI:10.2337/diacare.29.02.06.dc05-1267

PMID:16443905

Abstract

摘要

相似文献

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.

Diabetes Care. 2006 Feb;29(2):435-49. doi: 10.2337/diacare.29.02.06.dc05-1267.

Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.

Cleve Clin J Med. 2006 May;73(5):477-84. doi: 10.3949/ccjm.73.5.477.

Treatment evaluation of liraglutide in type 2 diabetes.

Expert Opin Biol Ther. 2012 Nov;12(11):1551-6. doi: 10.1517/14712598.2012.716823. Epub 2012 Aug 16.

New treatments of diabetes: the beta-amylin agonists.

Ann Endocrinol (Paris). 2008 Apr;69(2):147-50. doi: 10.1016/j.ando.2008.02.015. Epub 2008 Apr 18.

[Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].

G Ital Cardiol (Rome). 2011 Dec;12(12 Suppl 2):3-4. doi: 10.1714/985.10683.

Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.

Curr Drug Targets Immune Endocr Metabol Disord. 2002 Apr;2(1):63-82.

New therapies for diabetes.

Clin Cornerstone. 2007;8(2):58-63; discussion 64-5. doi: 10.1016/s1098-3597(09)60008-9.

New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).

J Assoc Physicians India. 2001 Jan 25;49 Spec No:46-9.

Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.

Diabet Med. 2002 Sep;19(9):790-2. doi: 10.1046/j.1464-5491.2002.00657_1.x.

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.

Arch Pharm Res. 2011 Jul;34(7):1041-3. doi: 10.1007/s12272-011-0721-z.

引用本文的文献

GLP-1-based therapies for diabetes, obesity and beyond.

Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8.

GLP-1 and Amylin in the Treatment of Obesity.

Curr Diab Rep. 2016 Jan;16(1):1. doi: 10.1007/s11892-015-0693-3.

New targets to treat obesity and the metabolic syndrome.

Eur J Pharmacol. 2015 Sep 15;763(Pt A):64-74. doi: 10.1016/j.ejphar.2015.03.093. Epub 2015 May 19.

Islet α cells and glucagon--critical regulators of energy homeostasis.

Nat Rev Endocrinol. 2015 Jun;11(6):329-38. doi: 10.1038/nrendo.2015.51. Epub 2015 Apr 7.

Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.

Nature. 2014 Jul 3;511(7507):94-8. doi: 10.1038/nature13297. Epub 2014 May 21.

The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.

Indian J Pharmacol. 2008 Jan;40(1):10-4. doi: 10.4103/0253-7613.40482.

Walnut consumption increases satiation but has no effect on insulin resistance or the metabolic profile over a 4-day period.

Obesity (Silver Spring). 2010 Jun;18(6):1176-82. doi: 10.1038/oby.2009.409. Epub 2009 Nov 12.

Pharmacotherapy for obesity.

Curr Atheroscler Rep. 2007 Dec;9(6):454-62. doi: 10.1007/s11883-007-0061-0.

Common crossroads in diabetes management.

Osteopath Med Prim Care. 2008 Feb 15;2:4. doi: 10.1186/1750-4732-2-4.

Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):579-90. doi: 10.1007/s00210-007-0232-0. Epub 2008 Jan 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.

Diabetes Care. 2006 Feb;29(2):435-49. doi: 10.2337/diacare.29.02.06.dc05-1267.

Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.

Cleve Clin J Med. 2006 May;73(5):477-84. doi: 10.3949/ccjm.73.5.477.

Treatment evaluation of liraglutide in type 2 diabetes.

Expert Opin Biol Ther. 2012 Nov;12(11):1551-6. doi: 10.1517/14712598.2012.716823. Epub 2012 Aug 16.

New treatments of diabetes: the beta-amylin agonists.

Ann Endocrinol (Paris). 2008 Apr;69(2):147-50. doi: 10.1016/j.ando.2008.02.015. Epub 2008 Apr 18.

[Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].

G Ital Cardiol (Rome). 2011 Dec;12(12 Suppl 2):3-4. doi: 10.1714/985.10683.

Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.

Curr Drug Targets Immune Endocr Metabol Disord. 2002 Apr;2(1):63-82.

New therapies for diabetes.

Clin Cornerstone. 2007;8(2):58-63; discussion 64-5. doi: 10.1016/s1098-3597(09)60008-9.

New pharmacological development (alpha glucosidase inhibitors, amylin analogues, GLP-1, thiozolidinediones, short acting insulin analogues).

J Assoc Physicians India. 2001 Jan 25;49 Spec No:46-9.

Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.

Diabet Med. 2002 Sep;19(9):790-2. doi: 10.1046/j.1464-5491.2002.00657_1.x.

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.

Arch Pharm Res. 2011 Jul;34(7):1041-3. doi: 10.1007/s12272-011-0721-z.

引用本文的文献

GLP-1-based therapies for diabetes, obesity and beyond.

Nat Rev Drug Discov. 2025 Apr 25. doi: 10.1038/s41573-025-01183-8.

GLP-1 and Amylin in the Treatment of Obesity.

Curr Diab Rep. 2016 Jan;16(1):1. doi: 10.1007/s11892-015-0693-3.

New targets to treat obesity and the metabolic syndrome.

Eur J Pharmacol. 2015 Sep 15;763(Pt A):64-74. doi: 10.1016/j.ejphar.2015.03.093. Epub 2015 May 19.

Islet α cells and glucagon--critical regulators of energy homeostasis.

Nat Rev Endocrinol. 2015 Jun;11(6):329-38. doi: 10.1038/nrendo.2015.51. Epub 2015 Apr 7.

Anti-diabetic activity of insulin-degrading enzyme inhibitors mediated by multiple hormones.

Nature. 2014 Jul 3;511(7507):94-8. doi: 10.1038/nature13297. Epub 2014 May 21.

The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.

Indian J Pharmacol. 2008 Jan;40(1):10-4. doi: 10.4103/0253-7613.40482.

Walnut consumption increases satiation but has no effect on insulin resistance or the metabolic profile over a 4-day period.

Obesity (Silver Spring). 2010 Jun;18(6):1176-82. doi: 10.1038/oby.2009.409. Epub 2009 Nov 12.

Pharmacotherapy for obesity.

Curr Atheroscler Rep. 2007 Dec;9(6):454-62. doi: 10.1007/s11883-007-0061-0.

Common crossroads in diabetes management.

Osteopath Med Prim Care. 2008 Feb 15;2:4. doi: 10.1186/1750-4732-2-4.

Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):579-90. doi: 10.1007/s00210-007-0232-0. Epub 2008 Jan 3.

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1.

作者信息

机构信息

出版信息

相似文献

引用本文的文献